These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27701095)

  • 1. A painstaking overhaul for cardiac safety testing.
    Servick K
    Science; 2016 Sep; 353(6303):976-977. PubMed ID: 27701095
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.
    Kraushaar U; Meyer T; Hess D; Gepstein L; Mummery CL; Braam SR; Guenther E
    Expert Opin Drug Saf; 2012 Mar; 11(2):285-98. PubMed ID: 22103746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ion channel profiling to advance drug discovery and development.
    Zou B
    Drug Discov Today Technol; 2015 Nov; 18():18-23. PubMed ID: 26723888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human pluripotent stem cell-derived cardiomyocyte based models for cardiotoxicity and drug discovery.
    Zhao Y; Korolj A; Feric N; Radisic M
    Expert Opin Drug Saf; 2016 Nov; 15(11):1455-1458. PubMed ID: 27560951
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting Drug Safety and Communicating Risk: Benefits of a Bayesian Approach.
    Lazic SE; Edmunds N; Pollard CE
    Toxicol Sci; 2018 Mar; 162(1):89-98. PubMed ID: 29126124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Pharmacology Society: 8th annual meeting.
    Cavero I;
    Expert Opin Drug Saf; 2009 Mar; 8(2):237-47. PubMed ID: 19309250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional cardiomyocytes from human stem cells: a tool for determining the cardiotoxic potential of preclinical drugs.
    Zeevi-Levin N; Itskovitz-Eldor J; Binah O
    Future Med Chem; 2013 Mar; 5(4):363-6. PubMed ID: 23495680
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
    Guo L; Abrams RM; Babiarz JE; Cohen JD; Kameoka S; Sanders MJ; Chiao E; Kolaja KL
    Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human embryonic stem cell derived cardiac myocytes detect hERG-mediated repolarization effects, but not Nav1.5 induced depolarization delay.
    Qu Y; Gao B; Fang M; Vargas HM
    J Pharmacol Toxicol Methods; 2013; 68(1):74-81. PubMed ID: 23518063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CiPA: Ongoing testing, future qualification procedures, and pending issues.
    Cavero I; Holzgrefe H
    J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
    Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
    Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes.
    Caspi O; Itzhaki I; Kehat I; Gepstein A; Arbel G; Huber I; Satin J; Gepstein L
    Stem Cells Dev; 2009; 18(1):161-72. PubMed ID: 18510453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
    Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
    J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond hERG.
    Jonsson MK; Vos MA; Mirams GR; Duker G; Sartipy P; de Boer TP; van Veen TA
    J Mol Cell Cardiol; 2012 May; 52(5):998-1008. PubMed ID: 22353256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.
    Braam SR; Tertoolen L; van de Stolpe A; Meyer T; Passier R; Mummery CL
    Stem Cell Res; 2010 Mar; 4(2):107-16. PubMed ID: 20034863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System.
    Xi B; Wang T; Li N; Ouyang W; Zhang W; Wu J; Xu X; Wang X; Abassi YA
    J Lab Autom; 2011 Dec; 16(6):415-21. PubMed ID: 22093298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model.
    Han X; Samieegohar M; Ridder BJ; Wu WW; Randolph A; Tran P; Sheng J; Stoelzle-Feix S; Brinkwirth N; Rotordam MG; Becker N; Friis S; Rapedius M; Goetze TA; Strassmaier T; Okeyo G; Kramer J; Kuryshev Y; Wu C; Strauss DG; Li Z
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106890. PubMed ID: 32574700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human stem cell models for predictive cardiac safety pharmacology.
    Braam SR; Mummery CL
    Stem Cell Res; 2010 May; 4(3):155-6. PubMed ID: 20493455
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.